(north)-methanocarbathymidine
Highest phase reached
Phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Small molecule
- Drug name
- (north)-methanocarbathymidine
- Molecular weight
- 252.27
- Structure (SMILES)
- Cc1cn([C@H]2C[C@H](O)[C@]3(CO)C[C@H]23)c(=O)[nH]c1=O
- (north)-methanocarbathymidine
- n mct
- n methanocarbathymidine
- N-mct
- N-methanocarbathymidine
- N-Methanocarbathymidine
- north methanocarbathymidine
- North-methanocarbathymidine
- CAS registry numbers
- 156126-12-4
- ChEMBL ID
- CHEMBL146673
- InChIKey
- NOWRLNPOENZFHP-ARHDFHRDSA-N
- PubChem compound IDs
- 445212
- FDA ingredient codes (UNII)
- LTM5S02010
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Condition identifier
- EFO_0000763
- Condition identifier
- EFO_0006510
- Highest recorded phase
- 1
- Condition identifier
- EFO_0011061
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005108
- Highest recorded phase
- 0
- Condition identifier
- MONDO_0005609
- Highest recorded phase
- 1
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 3
- Polar surface area
- 95.32
- Calculated partition coefficient (ALogP)
- -0.85
- Calculated partition coefficient (XLogP)
- -0.5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 18
- Molecular formula
- C12H16N2O4
- Monoisotopic mass
- 252.11100700
- Natural product
- No
- Recorded assays
- 67
- Active assays
- 17
- Confirmatory
- Other
Related records
Trials (4)
- A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism
- Emergency Treatment of Coral Snake Envenomation With Antivenom
- Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients
- Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China
In development for (1)
- Herpes zoster Phase 1